Positive VYVGART Data in Ocular MG, CIDP Supports Broader Use & Label Expansion
ARGX sits 66% above its 52-week low of $510.055.
Summary
ARGENX SE announced positive new clinical data for its key drug VYVGART at the American Academy of Neurology (AAN) 2026 Annual Meeting. The Phase 3 ADAPT OCULUS study met its primary endpoint, demonstrating VYVGART's efficacy in ocular myasthenia gravis (oMG), which will support a planned supplemental Biologics License Application (sBLA) submission to the FDA. Additionally, a post hoc analysis of ADHERE data showed VYVGART Hytrulo's potential for earlier use in treatment-naïve chronic inflammatory demyelinating polyneuropathy (CIDP) patients, with 87.5% achieving early benefit. These results significantly expand the potential market and revenue opportunity for VYVGART by demonstrating efficacy in new MG subtypes and supporting earlier intervention in CIDP. Investors should watch for the upcoming oMG sBLA submission and the FDA's target action date of May 10, 2026, for the generalized MG sBLA.
At the time of this announcement, ARGX was trading at $849.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.8B. The 52-week trading range was $510.06 to $934.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.